Skip to main content
. Author manuscript; available in PMC: 2026 Jun 13.
Published in final edited form as: J Clin Oncol. 2025 Jun 13;43(24):2692–2699. doi: 10.1200/JCO-25-00640

Table 3.

Non-Hematologic Adverse Events

Event1 All Grades n (%) Grade ≥3 n (%)
All 46 (77) 26 (43)
Infectious 25 (42) 22 (37)
All (non-infectious) 36 (60) 12 (20)
Hyperbilirubinemia 16 (27) 3 (5)
Diarrhea 12 (20) 1 (2)
Transaminitis 9 (15) 1 (2)
Acute kidney injury 8 (13) 0 (0)
Constipation 8 (13) 0 (0)
Nausea 8 (13) 0 (0)
Vomiting 5 (8) 1 (2)
Hypokalemia 4 (7) 0 (0)
Differentiation syndrome 3 (5) 2 (3)
Fatigue 3 (5) 0 (0)
Cough 2 (3) 0 (0)
Hyperphosphatemia 2 (3) 1 (2)
Hyperuricemia 2 (3) 0 (0)
QTc prolongation 2 (3) 1 (2)
Abdominal pain 1 (2) 1 (2)
Alopecia 1 (2) 0 (0)
Arthralgias 1 (2) 0 (0)
Hypomagnesemia 1 (2) 0 (0)
Hypocalcemia 1 (2) 0 (0)
Rash 1 (2) 0 (0)
Tumor lysis syndrome 1 (2) 1 (2)
1

At least possibly related while on protocol